UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2011

AMICUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-33497**	**71-0869350**
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6 Cedar Brook Drive, Cranbury, NJ	**08512**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **(609) 662-2000**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On January 11, 2011, John F. Crowley, President and Chief Executive Officer of Amicus Therapeutics, Inc. (the "Company"), participated in the 29th Annual J.P. Morgan Healthcare Conference (the "Conference"). A copy of the presentation given by Mr. Crowley at the Conference is attached to this Current Report as Exhibit 99.1. On the same date, the Company filed a press release, a copy of which is attached to this Current Report as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits: The Exhibit Index annexed hereto is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Amicus Therapeutics, Inc.

Date: January 11, 2011

By: /s/ Geoffrey P. Gilmore
Geoffrey P. Gilmore
Senior Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation Materials
99.2	Press Release dated January 11, 2011

Exhibit 99.1


Amicus
Therapeutics
JP Morgan Healthcare Conference
Jan 11, 2011
John F. Crowley, Chairman and CEO
At the Forefront of Therapies for Rare Diseases™
Nasdaq: FOLD
www.amicustherapeutics.com

Safe Harbor

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business, operations and financial conditions of Amicus including but not limited to preclinical and clinical development of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products, the projected cash position for the Company, and business development and other transactional activities. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "would," "should" and "could," and similar expressions or words, identify forward-looking statements. Although Amicus believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Actual results could differ materially from those projected in Amicus' forward-looking statements due to numerous known and unknown risks and uncertainties, including the "Risk Factors" described in our Annual Report on Form 10-K for the year ended December 31, 2009. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

Amicus Therapeutics

Industry Momentum in Rare Diseases

"In addition to our existing discovery effort, alternative opportunities need to be explored to make treatments available for rare diseases…. this new unit has the potential to deliver multiple therapies responding to high medical needs of underserved populations of patients."

- Marc Dunoyer, Global Head, GSK Rare Diseases

BIOWORLD®

Rare Disease is the Place to be

Amicus Lands $230M Deal for Fabry Chaperone Amigal

THE WALL STREET JOURNAL.

HEALTH INDUSTRY | SEPTEMBER 1, 2010, 10:38 A.M. ET

Pfizer Agrees to Acquire Drug Developer FoldRx

Bloomberg Businessweek

THE ASSOCIATED PRESS July 2, 2010, 9:11AM ET

Eli Lilly acquires biotech drug developer Alnara

The New York Times

Novartis takes rare road to cures

By Tom Wright
Published: Friday, July 8, 2005

InPharm

Pfizer forms rare diseases unit

By Dominic Tyer
Created 15/06/2010 - 08:46

Acceleron, Shire sign pact

Boston Business Journal - by Michelle Lang

Date: Thursday, September 9, 2010, 10:05am EDT - Last Modified: Thursday, September 9, 2010, 10:25am EDT

BIOWORLD®

Protalix: $115M Gaucher's Deal with Pfizer is Just the Beginning

By Trista Morrison

Amicus Therapeutics

Amicus: Building Shareholder Value in 2011

At the Forefront of Therapies for Rare Diseases™

Novel Pharmacological Chaperone Platform Technologies

Advanced Product Pipeline

Strong Partnership with GSK Rare Diseases

Pathway to More Prevalent Disorders through Rare Diseases

Amicus Therapeutics

Replacing ERTs in Lysosomal Storage Disorders
Pharmacological Chaperone Monotherapy

Slide 4



Improving ERTs in Lysosomal Storage Disorders
Pharmacological Chaperone Co-Administration

Next Generation Therapy: Enhancing ERT



~ 50% of Fabry patients

Amicus Therapeutics

Advanced Product Pipeline
Building Significant Rare Disease Franchise



Amigal for Fabry Disease
Disease Overview



- Lysosomal Storage Disease
- 5,000 – 10,000 patients worldwide
- Fabrazyme® and Replagal® ERTs current standard of care
- Current market: $800MM (est.)
- Males and Females

- GL-3 substrate accumulation
- Kidney, Heart and Brain
- Fatal

Amicus Therapeutics

Amigal for Fabry Disease
Clinical History of Amigal

- First in man: 2005
- 80+ patient-years of data
- 17 patients remain in Phase 2 extension study
  - 5 patients more than 4 years
  - 12 patients more than 3 years
- Phase 3 study ongoing

- Encouraging safety profile to date
  - No drug-related serious adverse events
  - No adverse event trends

Amicus Therapeutics

Amigal for Fabry Disease

Phase 2 Data Encouraging – Surrogate Endpoints

GL-3 Substrate Reduced

Primary Surrogate

Kidney Interstitial Capillary GL-3



Secondary Surrogate

Urine GL-3



Amigal for Fabry Disease

Phase 2 Data Encouraging – Clinical Endpoints

Renal Function

Proteinuria



eGFR



Amicus Therapeutics

Amigal for Fabry Disease
Phase 3 Study 011

Study Overview

- 60 patients, 6 month trial
- Primary Endpoint:
  - Amigal vs Placebo
  - ≥50% reduction in kidney interstitial capillary GL-3
- Enriched patient population
- Males and females

Status Update

- 36 sites initiated globally
- Majority of patients enrolled as of January
- Enrollment completion expected in 1H11
- Top-line results expected in 2H11

Amicus Therapeutics


Amicus
Therapeutics
Chaperone-ERT
Co-administration Therapy
At the Forefront of Therapies for Rare Diseases™

Improving ERTs for Lysosomal Storage Disorders
The Problem

Enzyme Replacement Therapies Denature Rapidly in Blood



Amicus Therapeutics

Improving ERT for Fabry Disease
Amigal + Fabrazyme Co-Administration

In pre-clinical studies, Amigal significantly increases Fabrazyme tissue uptake and markedly reduces GL-3 levels in kidney

Fabrazyme Kidney Tissue Uptake



GL-3 Levels in Kidney



Improving ERT for Pompe Disease
AT2220 + Myozyme Co-Administration

Amicus plans to perform a Phase 2 trial of AT2220 co-administered with ERT based on encouraging preclinical data

Myozyme Diaphragm Uptake



Glycogen Levels in Diaphragm




Amicus
Therapeutics
Partnership with GSK Rare Diseases
and Financial Outlook
At the Forefront of Therapies for Rare Diseases™

Strong Partnership with GSK Rare Diseases
Deal Announced in October 2010

"Amicus' scientific and clinical expertise in human genetic diseases is among the best in the industry, and we are pleased to be collaborators and investors in this exceptional company."

- Marc Dunoyer, Global Head, GSK Rare Diseases

"GSK has extremely impressive global clinical, regulatory and commercial expertise and a strong commitment to the development of treatments for rare diseases."

- John Crowley, Chairman and Chief Executive Officer, Amicus Therapeutics

Strong Partnership with GSK Rare Diseases
Exclusive Worldwide Rights for Amigal

Rationale

- Validation of potential for technology and Fabry program
- GSK clinical, regulatory, commercial and manufacturing expertise
- Financial strength and flexibility for Amicus

Deal Terms

- $30MM upfront license
- $31MM equity investment
- $170MM development + sales milestones
- Cost sharing on global development
  - 50/50 in 2011
  - 75 GSK/25 Amicus in 2012+
  - Tiered double digit royalties

Amicus Therapeutics

Strong Partnership with GSK Rare Diseases
Amicus Financial Strength

The GSK partnership allows Amicus to fully invest in Amigal and advance its pipeline while maintaining cash reserves

- Expected cash balance YE2010: ~ $100MM
- 2011 Projected Net Spend: $45-55MM
- Current cash along with anticipated GSK collaboration payments expected to be sufficient through anticipated Amigal U.S. commercial launch

Amicus Therapeutics

Further Opportunities in 2011

Building Shareholder Value Through Business Development

Amicus is actively exploring a range of business development opportunities with multiple potential partners

- R&D collaborations with pharmacological chaperone platform technology
- Partnerships and other opportunities to advance our neurodegenerative and chaperone-ERT co-administration programs
- Licensing transactions
- Strategic alliances

Amicus Therapeutics


Amicus
Therapeutics
Neurodegenerative Genetic Diseases
At the Forefront of Therapies for Rare Diseases™

Pathway to More Prevalent Disorders
Parkinson's and Gaucher: An Established Link

Mutations in the gene (*GBA*) now considered most common genetic risk factor for Parkinson's Disease

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

- Gaucher carriers have an estimated 5-fold increased risk for Parkinson's[1] Disease, and Gaucher patients have a 20-fold risk[2]
- Multiple independent studies in different populations
- Accumulation of alpha-synuclein is a leading target for new disease modifying therapies

[1]Sidransky, New Engl J Med, 2009 Oct 22; 361(17): 1651-61
[2]Bultron, Journal of Inherited Metabolic Disease, 2010, 33(2):167-173

Amicus Therapeutics

Pathway to More Prevalent Disorders
Collaboration with The Michael J. Fox Foundation

"I am pleased to continue working with Amicus on their exciting pharmacological chaperone approach to modify the progression of Parkinson's Disease. Amicus' earlier compound partially reversed the motor deficits in our alpha-synuclein overexpression mouse model, and we are eager to test the improved compounds."

- Marie-Françoise Chesselet, M.D., Ph.D., Charles H. Markham Professor of Neurology and Chair, Department of Neurobiology, David Geffen School of Medicine at UCLA

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH

"Currently available treatments for Parkinson's provide symptomatic relief only. Our therapy is designed to address a deficiency that is inherited in a subset of the Parkinson's population, and to actually modify the course of the disease."

- David J. Lockhart, Ph.D., Chief Scientific Officer, Amicus Therapeutics

Amicus Therapeutics

Pathway to More Prevalent Disorders
Significant Advancement in Parkinson's

Established proof-of-concept in Parkinson's animal models; increasing Gaucher enzyme (GCase) leads to marked synuclein reduction

Prevention of synuclein accumulation in the brain



Improvement in behavior and motor function



Amicus Therapeutics

Pathway to More Prevalent Disorders
Significant Improvement in Parkinson's Animals

The Pole Test:
A measurement of synuclein-dependent motor behavior





"...Amicus' compound partially reversed the motor deficits in our alpha-synuclein overexpression mouse model..."

- Marie-Françoise Chesselet, M.D., Ph.D., Charles H. Markham Professor of Neurology and Chair, Department of Neurobiology, David Geffen School of Medicine at UCLA

Amicus Therapeutics

Pathway to More Prevalent Disorders
Alzheimer's: Link to Lysosomal Storage Disorders


THE WALL STREET JOURNAL.

HEALTH INDUSTRY | DECEMBER 28, 2010

Key to Alzheimer's: Waste in Cells

By AMY DOCKSER MARCUS

Scientists have long known that an accumulation of waste products in the brain's cells can lead to neurodegenerative diseases. Now some are arguing that a similar process takes place in Alzheimer's disease and that by repairing the cells' ability to discard waste the disease can be stopped before it can cause damage.


PNAS

Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy

"The sheer bulk of waste proteins that are accumulating within the neurons in Alzheimer's disease brains is enormous…."

- Ralph A. Nixon, professor of psychiatry and cell biology , Langone Medical Center and the Nathan Kline Institute

Amicus Therapeutics

Pathway to More Prevalent Disorders

Amicus and Alzheimer's: A Pharmacological Chaperone Approach

Amicus is researching novel approaches to treating two distinct targets and patient populations within Alzheimer's Disease

Genetic (Familial) Alzheimer's	Sporadic Alzheimer's
▪ Presenillin-1 target ▪ Missense mutations ▪ 50,000-150,000 patients in U.S. ▪ Early pre-clinical POC established	▪ Lysosomal enzyme target ▪ ~4.5MM patients in U.S.

Amicus Therapeutics

Amicus: Building Shareholder Value in 2011

Amicus 2011 Expected Milestones

Ten milestones we expect to deliver in 2011

1H 2011

- 1st patient enrolled in Amigal/ERT co-admin study
- 1st patient enrolled in Amigal Ph 3 study 012
- Complete enrollment of Amigal Ph 3 study 011
- Amigal Ph 2 extension study data update
- Start AT2220/ERT co-admin study in Pompe

2H 2011

- Amigal/ERT co-admin study data in Fabry
- Complete Parkinson's preclinical, toxicology and manufacturing IND-enabling activities
- Amigal Ph 3 study 011 top-line results
- Alzheimer's further preclinical proof of concept in:
  - Presenilin-1 (Familial)
  - Lysosomal enzyme target (Sporadic)
- AT2220/ERT co-admin study data in Pompe

Amicus Therapeutics

Amicus: Building Shareholder Value in 2011

January 2011 Value Proposition

- Amicus is a leader in rare diseases
- ~ $125MM Market Cap
- ~ $100MM cash today
- Product and platform company
- Ten expected milestones in 2011
- Evaluating additional business development opportunities

Amicus Therapeutics


Amicus
Therapeutics
JP Morgan Healthcare Conference
Jan 11, 2011
John F. Crowley, Chairman and CEO
At the Forefront of Therapies for Rare Diseases™
Nasdaq: FOLD
www.amicustherapeutics.com

Exhibit 99.2

Amicus Therapeutics Provides 2011 Business Outlook and Expected Key Milestones

Significant progress expected to further establish Company as a leader in rare diseases

Cranbury, NJ, January 11, 2011 — Amicus Therapeutics (NASDAQ: FOLD) today will provide the Company's business outlook and expected key milestones for 2011 at the 29th Annual J.P. Morgan Healthcare Conference.

At the conference, Amicus is providing an update on its three key areas of focus: Amigal (migalastat hydrochloride) for the treatment of Fabry Disease, the evaluation of pharmacological chaperones co-administered with ERT, and the investigation of pharmacological chaperones for the treatment of diseases of neurodegeneration. The Company intends to identify key milestones expected in 2011 across these three areas, including results from the following studies:

- Phase 3 study of Amigal for Fabry Disease in 2H11
- Phase 2 study of Amigal co-administered with enzyme replacement therapy (ERT) for Fabry Disease in 2H11
- Phase 2 study of AT2220 co-administered with ERT for Pompe Disease in 2H11
- Late-stage preclinical proof of concept studies of AT3375 for Parkinson's Disease, including completion of additional IND-enabling activities, in 2H11.

"2011 promises to be a transformational year for Amicus. This is an exciting time in the rare disease field and we are uniquely positioned to develop new therapies for patients and to build value for our shareholders," said John F. Crowley, Chairman and CEO of Amicus. "This year we intend to achieve multiple milestones, led by our anticipated Phase 3 results for Amigal in Fabry Disease, which we expect to achieve in collaboration with our new partner, GSK Rare Diseases. In addition, we intend to move forward with Phase 2 studies evaluating chaperones co-administered with enzyme replacement therapy (ERT) in both Fabry and Pompe diseases. Finally, we expect important progress in our preclinical programs investigating the use of pharmacological chaperones in genetically defined sub-populations of Parkinson's disease and Alzheimer's disease. "

Financial Guidance

The Company expects to begin 2011 with a cash balance of approximately $100 million and to spend between $45 and $55 million on 2011 operating expenses (net of cost sharing and milestones related to GSK collaboration). The current cash position, including anticipated payments from GSK in connection with the collaboration, is expected to be sufficient to fund the Company's operations and capital expenditure requirements through the anticipated commercial launch of Amigal in the United States.

In 2011, the Company intends to evaluate additional business development opportunities to further build shareholder value. The Company indicates that it is actively exploring a range of opportunities with multiple potential partners.

Amigal (migalastat hydrochloride) for the treatment of Fabry Disease

On October 29, 2010, Amicus announced a definitive agreement with GlaxoSmithKline PLC (GSK) to develop and commercialize Amigal (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease. Under the terms of the agreement, GSK received an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl. Additionally, as part of the agreement, GSK and Amicus also intend to advance clinical studies exploring the co-administration of migalastat HCl with ERT for the treatment of Fabry disease.

The Phase 3 study (Study 011) of migalastat HCl remains the Company's number one priority. Study 011 is ongoing and patients are being enrolled at 36 investigational sites worldwide. A majority of the planned 60 patients have been enrolled in the study. The Company expects to complete enrollment in the first half of 2011 and to report preliminary results from this study in the second half of 2011.

Amicus and GSK intend to commence an additional Phase 3 study (Study 012) in the first quarter of 2011. Study 012 will be an 18-month, randomized, open-label study comparing migalastat HCl to enzyme replacement therapy (ERT) in approximately 60 subjects. The primary outcome of efficacy will be renal function as measured by glomerular filtration rate (GFR).

Chaperone-ERT Combination Therapy

Amicus previously reported promising preclinical data demonstrating that the co-administration of a pharmacological chaperone with ERT has the potential to address key limitations of ERT. The addition of a pharmacological chaperone has been shown to prevent the loss of activity of ERT in the circulation, increase tissue uptake, and increase substrate reduction. Preclinical proof of concept has been established for Fabry disease and Pompe disease.

Amicus and GSK intend to initiate a Phase 2 study with migalastat HCl co-administered with ERT for Fabry disease. This open-label Phase 2 study to investigate drug-drug interactions between migalastat HCl and ERT for Fabry disease is planned to commence in the first quarter of 2011 and results are expected in the second half of 2011.

Additionally, the Company expects to initiate a Phase 2 study with its pharmacological chaperone AT2220 co-administered with ERT for Pompe disease in the first half of 2011 and expects results from this study to be available in the second half of 2011. The Company intends to seek U.S. FDA approval to lift the current partial-hold on the AT2220 program as part of its development plan.

Diseases of Neurodegeneration

Amicus previously reported encouraging results from preclinical studies evaluating the use of a pharmacological chaperone for the treatment of Parkinson's Disease. Today Amicus will announce that in 2011 it expects to complete late stage preclinical proof of concept studies, including IND-enabling activities, for its pharmacological chaperone molecule AT3375, which is in development for the treatment of Parkinson's Disease. The Amicus Parkinson's Disease program is funded in part by a grant from The Michael J. Fox Foundation (MJFF).

Additionally, Amicus is reporting today that it continues to advance its preclinical program evaluating a pharmacological chaperone approach for the treatment of Alzheimer's disease. The Company expects to continue preclinical proof of concept studies during 2011. The Amicus Alzheimer's Disease program is funded in part by a grant from the Alzheimer's Drug Discovery Foundation (ADDF).

About Amicus Therapeutics

Amicus Therapeutics is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of rare diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program is in Phase 3 for the treatment of Fabry disease.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products, the projected cash position for the Company, including achievement of development and commercialization milestone payments and sales royalties under our collaboration with GlaxoSmithKline, and business development and other transactional activities that seek to strengthen the Company's financial position. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans, including achievement of development and commercialization milestone payments and sales royalties under our collaboration with GlaxoSmithKline. Additionally, with respect to statements relating to potential business development opportunities and other transactions that seek to strengthen our financial position, we may not be successful in identifying suitable collaborators, establishing and implementing such collaborations or completing other transactions that could improve our financial position. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2009. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

CONTACTS:

Investors/Media:
ir@amicustherapeutics.com
(609) 662-2000

FOLD—G